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Diabetes, both type 1 and type 2 (T2D), is a 
major threat to public health in the United 
States and abroad [Centers for Disease 
Control and Prevention (CDC) 2011; Danaei 
et al. 2011; World Health Organization 
(WHO) 2011]. Based on data from the 
2005–2008 National Health and Nutrition 
Examination Survey (NHANES), approxi-
mately 25.6 mil lion, or 11.3%, of all persons 
in the United States ≥ 20 years of age have 
diagnosed or undiagnosed diabetes, resulting 
in estimated direct medical costs and indirect 
costs (disability, work loss, premature death) 
of $174 billion in 2007 alone (CDC 2011). 
Another 35% of persons ≥ 20 years of age are 
prediabetic (American Diabetes Association 
2011; Knowler et al. 2002). Diabetes is 
now being diagnosed in individuals earlier 
in life [National Institute of Diabetes and 
Digestive and Kidney Diseases (NIDDK) 
2011]. Although approximately 70% of T2D 
is attributed to being overweight or obese 
(Eyre et al. 2004), 30% of T2D cases are not 
attributable to obesity. Given the number 
of persons impacted by T2D—346 million 
worldwide (WHO 2011)—and its long-term 
consequences in terms of morbidity, mortal-
ity, and economic costs, there is considerable 
interest in understanding the contribution 
of nontraditional risk factors to the diabetes 
 epidemic, including environ mental chemicals.
Research addressing the role of environ-
mental chemicals in diabetes manifestation has 
rapidly expanded. The February 2011 Diabetes 
Strategic Plan (NIDDK 2011) acknowledged 
the need to understand the role of environ-
mental exposures as part of future research 
and prevention strategies. To help develop 
such a research strategy, the National Institute 
of Environ mental Health Sciences/National 
Toxicology Program (NIEHS/NTP) orga-
nized a state-of-the-science workshop in 
January 2011 entitled Role of Environ mental 
Chemicals in the Development of Diabetes 
and Obesity (NTP 2011b). The objective 
of this workshop was to assess the literature 
for evidence of associations between diabe-
tes and/or obesity with chemicals, including 
arsenic, persistent organic pollutants, mater-
nal smoking during pregnancy, bisphenol A, 
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Background: Diabetes affects an estimated 346 million persons globally, and total deaths from 
 diabetes are projected to increase > 50% in the next decade. Understanding the role of environ mental 
chemicals in the development or progression of diabetes is an emerging issue in environ mental health. 
In 2011, the National Toxicology Program (NTP) organized a workshop to assess the literature for evi-
dence of associations between certain chemicals, including inorganic arsenic, and diabetes and/or obe-
sity to help develop a focused research agenda. This review is derived from discussions at that workshop.
oBjectives: Our objectives were to assess the consistency, strength/weaknesses, and biological 
plausibility of findings in the scientific literature regarding arsenic and diabetes and to identify data 
gaps and areas for future evaluation or research. The extent of the existing literature was insufficient 
to consider obesity as an outcome.
data sources, extraction, and synthesis: Studies related to arsenic and diabetes or obesity 
were identified through PubMed and supplemented with relevant studies identified by reviewing 
the reference lists in the primary literature or review articles.
conclusions: Existing human data provide limited to sufficient support for an association between 
arsenic and diabetes in populations with relatively high exposure levels (≥ 150 µg arsenic/L in drink-
ing water). The evidence is insufficient to conclude that arsenic is associated with diabetes in lower 
exposure (< 150 µg arsenic/L drinking water), although recent studies with better measures of out-
come and exposure support an association. The animal literature as a whole was inconclusive; how-
ever, studies using better measures of diabetes-relevant end points support a link between arsenic 
and diabetes. 
key words: animal, arsenic toxicity, cell line, chemically induced/epidemiology, cultured cell, dia-
betes, environ mental epidemiology, glucose, insulin, metabolism, obesity. Environ Health Perspect 
120:1658–1670 (2012). http://dx.doi.org/10.1289/ehp.1104579 [Online 10 August 2012]
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phthalates and organotins, and nonpersistent 
pesticides (Thayer et al. 2012). This report 
is derived from discussions on arsenic that 
occurred at the workshop.
The arsenic evaluation focused on diabetes 
only, as studies have not assessed obesity as a 
primary health outcome. Our review focused 
on the a) consistency, strength/weaknesses, 
and biological plausibility of findings, b) iden-
tification of the most useful and relevant end 
points in experimental animals and mechanis-
tic studies, and c) identification of data gaps 
and areas for future evaluation/research.
Identification of Relevant 
Studies
A PubMed (National Library of Medicine, 
Washington, DC, USA) search strategy, first 
conducted on 24 August 2009 and then run 
weekly until 15 December 2010, was devel-
oped to identify human, animal, and mecha-
nistic studies (including in vitro assays) on 
arsenic exposures related to diabetes and obe-
sity using MeSH (Medical Subject Headings)-
based and keyword strategies [for search terms, 
see Supplemental Material, p. 2 (http://dx.doi.
org/10.1289/ehp.1104579)]. A total of 108 
publications were identified from the search, 
and 38 of those presented original data con-
cerning both arsenic exposure and diabetes 
(or diabetes- related end points and/or mecha-
nisms) and were considered relevant (see 
Supplemental Material, Figure S1). An addi-
tional 38 studies were identified during the 
course of the initial primary literature review 
and discussions with workshop participants, 
including two studies that had been submit-
ted but not yet accepted for publication (Del 
Razo et al. 2011; Paul et al. 2011), for a total 
of 76 studies considered as the final primary 
literature. Two of these studies included more 
than one type of data, human and animal 
(Wang et al. 2009) or animal and in vitro (Yen 
et al. 2007). 
One goal of the review was to assess the 
scientific literature using the descriptors “suf-
ficient,” “limited,” or “insufficient” to clas-
sify existing evidence, with NTP definitions 
utilized for the NTP Report on Carcinogens 
as a framework for “sufficient” and “lim-
ited” (NTP 2011a). “Sufficient” evidence for 
human studies indicates a causal relationship 
between exposure to the agent, substance, or 
mixture and an outcome based on evidence of 
a dose–response and other characteristics such 
as consistency and coherence among different 
studies, adequate control for other covariates, 
biological plausibility, and adequate identifi-
cation of sources of potential bias. “Limited” 
evidence indicates that causal interpretation is 
credible but that alternative explanations, such 
as chance, bias, or confounding factors could 
not adequately be excluded. The term “insuf-
ficient” is used when there is low confidence 
in the body of evidence to reach a conclusion 
on the association between exposure to a sub-
stance and health outcome(s) or when no data 
are available.
Epidemiological studies were classified as 
a) occupational studies; b) population-based 
studies in areas with relatively high environ-
mental arsenic exposure (≥ 150 µg/L in drink-
ing water); c) population-based studies in areas 
with lower arsenic exposure (< 150 µg/L in 
drinking water) excluding NHANES studies; 
and d) NHANES studies. The cut points used 
for drinking-water arsenic were selected to dis-
tinguish between high-exposure studies in areas 
with unusually high exposures via drinking 
water (e.g., in areas of Taiwan and Bangladesh) 
and low-to-moderate exposure studies. 
Epidemiological Studies
The first epidemiological studies reporting 
associations between arsenic and diabetes were 
published in the mid-1990s. These early stud-
ies were conducted in populations exposed 
to high levels of arsenic in drinking water in 
Taiwan and Bangladesh or were occupational 
studies of copper smelter and glass workers 
in the United States and Europe exposed to 
dust and particulates as distinct from water. 
Previous reviews of studies published before 
2008 concluded that arsenic exposure was 
most consistently associated with diabetes in 
areas of Taiwan and Bangladesh with high 
arsenic contamination of drinking water in 
the past, whereas results from occupational 
studies and studies of populations with low-
to-moderate arsenic levels in drinking water 
were inconsistent (Chen et al. 2007; European 
Food Safety Authority 2009; Longnecker and 
Daniels 2001; Navas-Acien et al. 2006; Tseng 
et al. 2002). More than 10 new epidemio-
logical studies of arsenic exposure and diabetes 
have been published since 2007. 
Detailed descriptions of all of the epidemio-
logical studies considered for the review can 
be found in the technical literature review 
document prepared for the NTP workshop 
(NTP 2011b). Eight occupational studies 
also were considered as part of the review [see 
Supplemental Material, Table S1 (http://
dx.doi.org/10.1289/ehp.1104579)] but are not 
considered further in this report because of 
concerns about diabetes assessment, exposure 
misclassification, and limited power. Most of 
the occupational studies ascertained diabetes 
based on death certificates, which are well 
known to have low sensitivity and specificity 
for diabetes (Cheng et al. 2008). In addition, 
arsenic exposure was determined based on 
job title, and with one exception (Lubin et al. 
2000) the sample size or number of individuals 
with diabetes was small. This assessment of the 
occupational studies is consistent with other 
reviews of arsenic (Longnecker and Daniels 
2001; Navas-Acien et al. 2006). 
Environ mental exposure settings. Of the 
27 eligible nonoccupational publications that 
met our inclusion criteria, 9 were classified as 
high exposure (Table 1), 15 were classified as 
non-NHANES studies with low-to-moderate 
exposure (Table 2), 1 was classified as both 
low and high exposure (Chen et al. 2010), and 
4 were classified as analyses of NHANES data 
(Table 2). Two high- exposure studies used a 
prospective design (Tseng et al. 2000a, 2000b), 
and the rest were cross-sectional (n = 12, 
excluding the NHANES studies), case–control 
(n = 5), or retrospective (n = 4). Three stud-
ies did not report risk estimates for diabetes, 
but compared the levels of arsenic in persons 
with diabetes (diabetics) and non diabetics 
(Afridi et al. 2008; Kolachi et al. 2010; Serdar 
et al. 2009).
Diabetes ascertainment differed among 
studies. Four studies used death certificates to 
ascertain diabetes (Lewis et al. 1999; Meliker 
et al. 2007; Tollestrup et al. 2003; Tsai et al. 
1999) and three others used exclusively self-
reported history of diabetes (Afridi et al. 2008; 
Chen et al. 2010; Zierold et al. 2004). Two 
studies used diagnosis of diabetes but did not 
report the basis of diabetes diagnosis (Ruiz-
Navarro et al. 1998; Ward and Pim 1984). 
Seven studies, generally those conducted more 
recently, incorporated diagnostic indicators 
such as fasting glucose or oral glucose toler-
ance test (OGTT) results (Coronado-González 
et al. 2007; Del Razo et al. 2011; Ettinger 
et al. 2009; Kolachi et al. 2010; Rahman et al. 
1998; Tseng et al. 2000b; Wang et al. 2007). 
Two other studies reported risk estimates for 
metabolic syndrome (Wang et al. 2007) and 
impaired glucose tolerance (Ettinger et al. 
2009) rather than diabetes. Many of the 
studies were conducted in Bangladesh [n = 4 
(Chen et al. 2010; Nabi et al. 2005; Rahman 
et al. 1998, 1999)] or Taiwan [n = 5 (Lai et al. 
1994; Tsai et al. 1999; Tseng et al. 2000b; 
Wang et al. 2003, 2007)]. Other countries 
included the United States (Ettinger et al. 
2009; Lewis et al. 1999; Meliker et al. 2007; 
Navas-Acien et al. 2008, 2009a; Steinmaus 
et al. 2009a, 2009b; Tollestrup et al. 2003; 
Zierold et al. 2004), Mexico (Coronado-
González et al. 2007; Del Razo et al. 2011), 
Pakistan (Afridi et al. 2008; Kolachi et al. 
2010), Turkey (Serdar et al. 2009), Spain 
(Ruiz-Navarro et al. 1998), China (Wang 
et al. 2009), and the United Kingdom (Ward 
and Pim 1984).
Measures of exposure are highly variable 
between these studies, ranging from area-
wide exposure estimates based on measure-
ment of arsenic from drinking-water sources 
to  individual-level exposure estimates based 
on detailed water consumption history, 
work history, or actual biomarkers of expo-
sure. These variations in study design con-
stitute irreducible sources of heterogeneity 
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and present interpretive challenges in evalu-
ating the results observed in this collection 
of studies. Specifically, exposure was assessed 
by arsenic concentrations in drinking water 
within a geographic area (Del Razo et al. 2011; 
Meliker et al. 2007; Zierold et al. 2004), as 
cumulative exposure index based on residence 
time × average drinking- water level (Chen 
et al. 2010; Lai et al. 1994; Lewis et al. 1999; 
Rahman et al. 1999; Tseng et al. 2000b), resi-
dence time in an arsenicosis-endemic region 
(Tollestrup et al. 2003; Tsai et al. 1999; Wang 
et al. 2003) or presence or absence of arsenico-
sis or keratosis as a surrogate for long-term 
exposure to arsenic (Nabi et al. 2005; Rahman 
et al. 1998) or by biomarkers including blood/
plasma arsenic levels (Ettinger et al. 2009; 
Serdar et al. 2009; Ward and Pim 1984) and 
arsenic concentration in urine (Coronado-
González et al. 2007; Navas-Acien et al. 2008, 
2009a; Ruiz-Navarro et al. 1998; Steinmaus 
et al. 2009a, 2009b; Wang et al. 2009) or hair 
(Afridi et al. 2008; Kolachi et al. 2010; Wang 
et al. 2007). Three studies did not report risk 
estimates, but compared the levels of arsenic 
in diabetics and non diabetics. Afridi et al. 
(2008) measured higher levels of arsenic in 
the hair, blood, and urine of 196 diabetics 
participating in a study that included a total of 
434 men from Hyderabad, Pakistan. Higher 
arsenic urine, blood, and hair levels were also 
found in diabetics compared to non diabetics 
in another study conducted in Pakistan by 
Kolachi et al. (2010). Levels of hair arsenic 
were significantly higher in a group of 76 new 
mothers with insulin- dependent diabetes com-
pared to a group of 68 non diabetic mothers, 
although hair is not considered the preferred 
matrix for arsenic [National Research Council 
(NRC) 1999]. Serdar et al. (2009) did not 
detect any statistically significant differences 
in plasma arsenic in diabetes cases (n = 31, 
mean ± SD = 1.22 ± 0.57 µg/L) compared 
to controls [n = 22; mean (range) = 0.86 
(0.64–1.59 µg/L)] in a study based in Turkey, 
although this study may have been under-
powered to detect differences. 
Environ mental exposure, high arsenic 
areas (≥ 150 µg/L drinking water). Table 1 
summarizes the high-arsenic environ mental 
exposure studies from Bangladesh (Chen 
et al. 2010; Nabi et al. 2005; Rahman et al. 
1998, 1999) and Taiwan (Lai et al. 1994; 
Tsai et al. 1999; Tseng et al. 2000a, 2000b; 
Wang et al. 2003). There is limited to suf-
ficient evidence for an association between 
arsenic and diabetes in populations from 
high-arsenic areas, primarily occurring in 
Bangladesh or Taiwan. Support for an asso-
ciation was strongest in studies where arsenic 
drinking- water levels were > 500 µg/L (Lai 
et al. 1994; Nabi et al. 2005; Rahman et al. 
1998, 1999; Tsai et al. 1999; Tseng et al. 
2000b; Wang et al. 2003). Eight of the nine 
studies conducted in Taiwan or Bangladesh 
reported positive associations between arsenic 
and diabetes (Table 1) (Lai et al. 1994; Nabi 
et al. 2005; Rahman et al. 1998, 1999; Tsai 
et al. 1999; Tseng et al. 2000a, 2000b; Wang 
et al. 2003). The only prospective study within 
this group also reported a positive associa-
tion [adjusted relative risk (RR) = 2.1 (95% 
CI: 1.1, 4.2)] for development of diabetes 
over a 4-year follow-up period among indi-
viduals with ≥ 17 mg/L-years compared with 
< 17 mg/L-years cumulative arsenic exposure 
(Tseng et al. 2000b). Those studies relying on 
clinically accepted measures of disease (e.g., 
fasting blood glucose, OGGT) (Lai et al. 
1994; Rahman et al. 1998; Tseng et al. 2000a, 
2000b) reported risk estimates ranging from 
Table 1. Association between arsenic and diabetes in areas of relatively high exposure (≥ 150 µg/L drinking water).
Reference 




Chen et al. 2010 
(cross-sectional)
Bangladesh (Araihazar) 
HEALS, n = 11,319 
♂♀ 
Self-report prior to 
baseline
1.11 (95% CI: 0.73, 1.69) 
adjOR
176.2–864 (Q5) vs. 0.1–8 (Q1) µg As/L drinking 
water, CEI 
Cohort: 0.1–864 µg As/L








n = 891 ♂♀ 
Self-report, OGTT, 
treatment history
10.05 (95% CI: 1.3, 77.9) 
adjOR
≥ 15 vs. 0 ppm-year drinking water, CEI 
Cohort: 780 (700–930) µg As/L; median (range) 
concentrations in artesian wellsd 
Age, sex, BMI, 
physical activity





n = 235 ♂♀
Glucose, blood 2.95 (95% CI: 0.954, 9.279) 
OR
218.1 vs. 11.3 (mean) µg As/L drinking water 
Cohort: 218.1 (3–875) µg As/L; mean (range)
Unadjusted
Rahman et al. 1998f 
(cross-sectional)
Bangladesh (Dhaka) 
keratosis cases,  
n = 1,107 ♂♀ 
Self-report, OGTT, 
glucosuria
5.2 (95% CI: 2.5, 10.5) 
adjPR
Keratosis vs. non-keratosis
Cohort: < 10–2,100 µg As/L
Age
Rahman et al. 1999f 
(cross-sectional)
Bangladesh (multisite) 
with skin lesions,  
n = 430 ♂♀
Glucosuria 2.9 (95% CI: 1.6, 5.2) 
adjPR
> 10 vs. < 1 mg-year As/L drinking water, CEI 
Cohort: < 500 to > 1,000 µg As/L drinking water
Age, sex, BMI
Tsai et al. 1999e 
(retrospective)
Taiwan (Chiayi County) 
Blackfoot region, 
n = 19,536 deaths ♂♀ 
Death certificate 1.46 (95% CI: 1.28, 1.67) 
SMR
Blackfoot endemic region vs. national reference
Cohort: 780 (250–1,140) µg As/L; median (range)
Age, sex





n = 446 ♂♀
Fasting blood 
glucose, OGTT
2.1 (95% CI: 1.1, 4.2)  
RR
≥ 17 vs. < 17 mg/L-year As (drinking water, CEI)
Cohort: 700–930 µg As/L; range of median 
concentration in artesian wells
Age, sex, BMI




n = 706,314 ♂♀
Insurance claims 2.69 (95% CI: 2.65, 2.73) 
adjOR
Endemic vs. non-endemic region 
Cohort: 780 (350–1,140) µg As/L; median (range)d
Age, sex
Abbreviations: adjOR, adjusted odds ratio; adjPR, adjusted prevalence ratio; As, arsenic; BMI, body mass index; CEI, cumulative exposure index; HEALS, Health Effects of Arsenic 
Longitudinal Study; mg-year, milligram year; OGTT, oral glucose tolerance test; OR, odds ratio; Q, quintile; RR, relative risk; SMR, standardized mortality ratio. 
aIdentification of main findings was based on the following strategy: for studies that did not report a significant association between arsenic exposure and a health outcome at any 
exposure level, the main summary finding was based on the highest exposure group compared to the referent group (e.g., 4th quartile vs. 1st quartile). When a study reported a signifi-
cant association between arsenic exposure and a health outcome, the main finding was based on lowest exposure group where a statistically significant association was observed 
(e.g., 3rd quartile vs. 1st quartile). bUnless specified, relative risk estimates are crude estimates. cMedian or mean and range of As concentration in drinking water for the cohort is 
included when reported. dArsenic drinking- water concentrations were taken from other publications based on same populations. eCalculated by entering data presented in publica-
tion into OpenEpi software (Dean et al. 2011). fAlthough the arsenic water concentrations are expressed in units of mg/L, the value is supposed to represent the “approximate time-
weighted mean arsenic exposure levels that were calculated over the lifetime of each subject as ∑j (ajcj /∑j aj, where aj is the number of years a well with arsenic concentration cj 
was used, assuming that the current levels of arsenic in the well water were also representative of the past source.” gThere appears to be an error in the number of persons included 
in the “non-endemic” area category based on the ns provided in Table 1 of Wang et al. 2003. 
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2.1 (RR; 95% CI: 1.1, 4.2) to 10.05 [adjusted 
odds ratio (adjOR); 95% CI: 1.3, 77.9]. 
Some of the studies might not be completely 
independent if they were surveying the same 
population, and perhaps the same individu-
als. Of the studies conducted in Taiwan, sev-
eral (Lai et al. 1994; Tsai et al. 1999; Tseng 
et al. 2000b; Wang et al. 2003) derived their 
study populations from the Southwestern 
Blackfoot or arseniasis-endemic region of 
Taiwan. Furthermore, several papers specifi-
cally included the village of Pu-Tai (Lai et al. 
1994; Tseng et al. 2000a, 2000b). Data pre-
sented by Tseng et al. (2000a, 2000b) repre-
sent a follow-up to the Lai et al. (1994) study 
and therefore likely included many of the same 
participants. Studies conducted in Bangladesh 
have focused on the same geographical area for 
their exposed populations: Dhaka, Rajshahu, 
and Khulna Divisions (Chen et al. 2010; Nabi 
et al. 2005; Rahman et al. 1998, 1999). While 
none of the Bangladesh studies indicated that 
they were follow-up activities related to previ-
ous studies, participants may have overlapped. 
In contrast to the relative strength and 
consistency of results in many of the high-
exposure studies, the most recent and largest 
study in Bangladesh did not find any signifi-
cant associations between urinary arsenic or 
time-weighted average water arsenic and self-
reported diabetes, glucosuria, or hemoglobin 
A1c (HbA1c) levels in a population-based 
cross-sectional study of 11,319 Bangladeshi 
men and women participating in the Health 
Effects of Arsenic Longitudinal Study 
(HEALS) (Chen et al. 2010). Diagnosis of 
diabetes was based on self-report of physician 
diagnosis prior to baseline, glucosuria (exclud-
ing 90 individuals who were taking medica-
tions for diabetes), or, in a smaller subset of 
2,100 participants, HbA1c. Although the 
Chen et al. (2010) cohort is large, statistical 
power was limited by the small number of 
diabetes cases (241 of 11,078; about 2% of 
the total cohort reported a diagnosis of dia-
betes prior to baseline, including 45 diabetes 
cases in the highest quintile category for time-
weighted average arsenic). Nonetheless, while 
a number of explanations for the findings of 
Chen et al. (2010) exist, no definitive conclu-
sions could be drawn regarding aspects of the 
Table 2. Association between arsenic and diabetes-related measures in areas of relatively low-to-moderate exposures (< 150 µg/L drinking water) and NHANES.
Reference (study design) Location, subjects Diabetes diagnosis Main findinga,b Exposurec
Factors considered 
in analysis
Afridi et al. 2008d 
(cross-sectional)
Pakistan (Hyderabad), 
n = 225 ♂ (nonsmokers) 
and n = 209 ♂ (smokers) 
Self-report ↑ Urinary As in nonsmoking 
diabetics
Nonsmokers: 5.59 (diabetics) vs. 4.7 
(non diabetics) µg As/L, mean (urine)
Smokers: 7.27 (diabetics) vs. 5.41 
(non diabetics) µg As/L 
Cohort: drinking- water concentrations 
not reported
Unadjusted
Chen et al. 2010 
(cross-sectional)
Bangladesh (Araihazar), 
HEALS, n = 11,319 ♂♀ 
Self-report prior to 
baseline
1.24 (95% CI: 0.82, 1.87) 
adjOR
41–92 (Q3) vs. 0.1–8 (Q1) µg As/L 
drinking water, CEI 
Cohort: 0.1–864 µg As/L
Age, sex, BMI, smoking 
status, educational 
attainment; (similar 
results obtained when 
model only adjusted for 
age, sex, BMI)
Coronado-González 




n = 400 ♂♀
Fasting blood glucose, 
treatment history
2.84 (95% CI: 1.64, 4.92) 
adjOR
> 104 (T3) vs. < 63.5 (T1) µg As/g 
creatinine (urine) 
Cohort: 20–400 µg As/L drinking water 
reported in other studies of the region
Age, sex, hypertension, 
family history, obesity, 
serum lipids
Del Razo et al. 2011 
(cross-sectional)
Mexico (Zimapan and 
Lagunera) As-endemic 
region, n = 258 ♂♀
Fasting blood glucose 1.13 (95% CI: 1.05, 1.22) 
adjOR per 10 µg As/L ↑
Cohort: 42.9 mean (3–215, range) µg 
As/L (current drinking water)
Age, sex, obesity, 
hypertension
Ettinger et al. 2009 
(cross-sectional)
USA (Tar Creek, OK), 
n = 456 pregnant ♀
Impaired glucose 
tolerance (OGTT)
2.79 (95% CI: 1.13, 6.87) 
adjOR
2–24 (Q4) vs. 0.2–0.9 (Q1) µg As/L 
(blood) 
Cohort: reported from other studies that 
at least 25% of samples in region have 
> 10 µg As/L drinking water 
Age, pre-pregnancy 
BMI, ethnicity/race, 
Medicaid use, married 
or living with partner
Kolachi et al. 2010 
(case–control)
Pakistan (Hyderabad) 
diabetes, n = 144 ♀
IDDM (fasting blood 
glucose, OGTT)
↑ Urine As in diabetics 4.13 (diabetics) vs. 1.48 (non diabetics) µg 
As/L, mean (urine) 
Cohort: drinking- water concentrations 
not reported
Unadjusted
Lewis et al. 1999 
(retrospective)
USA (7 communities in 
Millard County, UT), 
n = 961 ♀ deaths; 
n = 1,242 ♂ deaths
Death certificate ♀: 1.23 (95% CI: 0.86, 1.71) 
SMR 
♂: 0.79 (95% CI: 0.48, 1.22) 
SMR
Millard vs. state 
Cohort: 14–166 µg (3.5–620) µg As/L, 
range of median well-water 
concentrations between 1976–1997 
(overall range)
Sex, race
Meliker et al. 2007 
(retrospective)
USA (6 counties in 
southeastern MI), 
n = 41,282 ♂ deaths; 
n = 38,722 ♀ deaths
Death certificate ♂: 1.28 (95% CI: 1.18, 1.37) 
SMR
♀: 1.27 (95% CI: 1.19, 1.35) 
SMR
6 counties vs. state µg As/L (drinking 
water) 
Cohort: 7.58 (1.27–11.98) µg As/L, 
population weighted median across 
6 counties (range)
Sex, race
Ruiz-Navarro et al. 
1998e (case–control)
Spain (Motril) hospital 
patients, n = 87 ♂♀
Not reported 0.87 (95% CI: 0.5, 1.53) RR 75th vs. 25th percentile µg As/L (urine) 
Cohort: drinking- water concentrations 
not reported
Unadjusted
Serdar et al. 2009 
(cross-sectional)
Turkey (Ankara), n = 87 
diabetes clinic patients
Treatment history ↔ Plasma As in diabetics 
vs. controls
1.22 (diabetics) vs. 0.86 (non diabetics) µg 
As/L (plasma) 
Cohort: drinking- water concentrations 
not reported
Unadjusted
Tollestrup et al. 2003e 
(retrospective)
USA (Ruston, WA) lived 
near smelter as children, 
n = 1,074 deaths ♂♀ 
Death certificate 1.6 (95% CI: 0.36, 7.16) RR Residence time within 1.6 km (1 mi): 
≥ 10 years vs. < 1 year 
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study design or population (e.g., nutritional 
status, obesity, genetic differences) or exposure 
history (i.e., the relatively short duration of 
exposure for some study participants com-
pared with the experiences of individuals in 
the arsenic-contaminated areas of Taiwan) 
that could explain the difference between this 
and the other studies. 
Environ mental exposure, low-to-moderate 
arsenic areas. Excluding the NHANES stud-
ies, 12 of the 15 identified epidemiologic stud-
ies reported risk estimates related to diabetes, 
glycemic control, or metabolic syndrome 
in popu lations under conditions of low-
to-moderate arsenic exposure from drinking 
water (< 150 µg/L drinking water) (Table 2). 
Two studies (Lewis et al. 1999; Meliker et al. 
2007) evaluated SMRs for each sex sepa-
rately. The highest categories of drinking-
 water exposure in these studies were lower 
than the arsenic-exposed population studies in 
Bangladesh and Taiwan. Overall, the current 
literature provides insufficient evidence to con-
clude that arsenic is associated with diabetes at 
these levels of exposure. Recent studies with 
better measures of outcome (fasting blood glu-
cose levels or OGTT) reported more consis-
tent associations between arsenic and diabetes 
(Coronado-González et al. 2007; Del Razo 
et al. 2011) or impaired glucose tolerance 
(Ettinger 2009) within this range of exposure. 
Some of the differences among the studies 
may be due to variation in sample sizes and to 
differences in study populations and methods 
used to classify diabetes (e.g., death certificates 
vs. self-report or blood glucose level) or to 
estimate arsenic exposure (e.g., urine levels vs. 
drinking-water surveys).
Four publications based on analyses of 
data from NHANES cohorts, which are 
representative of the U.S. population and gen-
erally include participants with low-to-moderate 
exposure, were considered in our review 
(Navas-Acien et al. 2008, 2009a; Steinmaus 
et al. 2009a, 2009b). However, the results of 
these studies should not be considered inde-
pendent because the main focus of several of 
the publications was to compare the methodo-
logical strategies used to assess the association 
between urinary arsenic and diabetes. In brief, 
differences in interpretation of the association 
between arsenic and diabetes can be reached 
based on different methodological approaches 
used to account for organic arsenic due to sea-
food consumption and whether to include 
urinary creati nine as an adjustment factor in 
the statistical model. Results of two of the 
NHANES analyses supported an association 
between arsenic exposure and diabetes (Navas-
Acien et al. 2008, 2009a), but results based 
Table 2. Continued
Reference (study design) Location, subjects Diabetes diagnosis Main findinga,b Exposurec
Factors considered 
in analysis
Wang SL et al. 2007 
(cross-sectional)
Taiwan (central) industrial 






2.35 (95% CI: 1.02, 5.43) 
adjOR
“High” vs. “low” µg As/g hair 
Cohort: 2002–2005 groundwater 
concentrations for area ranged from 
~6 to ~15 µg As/L 
Age, sex, occupation, 
lifestyle factors 
(alcohol, betel nut 
chewing, smoking, 
groundwater use)
Wang JP et al. 2009f 
(cross-sectional)
China (Xinjiang region) 
As-endemic region, 
n = 235 ♂♀
Hospital records, 
exam
1.098 (95% CI: 0.98, 1.231) 
RR
21–272 (range) vs. 16–38 (range) µg As/L 
(drinking water) 
Cohort: 16–272 µg As/L drinking water
Unadjusted
Ward and Pim 1984f 
(case–control)
U.K. (Oxford, England) 
diabetes clinic patients, 
n = 117 ♂♀
Not reported 1.09 (95% CI: 0.79, 1.49) 
RR
75th vs. 25th percentile µg As/mL 
(plasma) 
Cohort: drinking- water concentrations 
not reported
Unadjusted
Zierold et al. 2004g 
(cross-sectional)
U.S. (WI) well-water 
testing program, 
n = 1,185 ♂♀
Self-report 1.02 (95% CI: 0.49, 2.15) 
adjOR
> 10 vs. < 2 µg As/L (well-water) 
Cohort: 2 (0–2,389) µg As/L; median 
(range)
Age, sex, BMI, smoking
Navas-Acien et al. 2008 
(cross-sectional)
U.S. (NHANES 2003–2004) 




3.58 (95% CI: 1.18, 10.83) 
adjOR
18 (≥ 80th) vs. 3.5 (≤ 20th percentile) 
µg As/L (urine)
Sex, age, race, urine 
creatinine, education, 





Navas-Acien et al. 
2009a (cross-sectional)
U.S. (NHANES 2003–2006) 
≥ 20 years, n = 1,279 





2.60 (95% CI: 1.12, 6.03) 
adjOR
7.4 (80th) vs. 1.6 (20th percentile) 
µg As/L (urine)
Sex, age, race, urine 
creatinine, education, 




Steinmaus et al. 2009a 
(cross-sectional)
U.S. (NHANES 2003–2004) 




1.15 (95% CI: 0.53, 2.50) 
adjOR
12 (≥ 80th) vs. 2.7 ( ≤ 20th percentile) 
µg As/L (urine, not adjusted for 
creatinine) [urine As = total As – 
(arsenobetaine + arsenocholine)]
Sex, age, ethnicity, 
education, BMI, 
serum cotinine, urine 
creatinine, current 
use of hypertension 
medications 
Steinmaus et al. 2009b 
(cross-sectional)
U.S. (NHANES 2003–2006) 
≥ 20 years, n = ~1,280 





1.03 (95% CI: 0.38, 2.80) 
adjOR
≥ 80th vs. ≤ 20th percentile µg As/L 
(urine, not adjusted for creatinine)
Sex, age, race, BMI
Abbreviations: adjOR, adjusted odds ratio; adjPR, adjusted prevalence ratio; As, arsenic; BMI, body mass index; CEI, cumulative exposure index; HDL, high density lipoproteins; IDDM, 
insulin dependent diabetes mellitus; LOD, level of detection; MI, Michigan; OK, Oklahoma; Q, quintile; RR, relative risk; SMR, standardized mortality ratio; T, tertile; UT, Utah; WA, 
Washington. 
aIdentification of main findings was based on the following strategy: For studies that did not report a significant association between arsenic exposure and a health outcome at any expo-
sure level, the main summary finding was based on the highest exposure group compared to the referent group (e.g., 4th quartile vs. 1st quartile). When a study reported a significant 
association between arsenic exposure and a health outcome, the main finding was based on lowest exposure group where a statistically significant association was observed (e.g., 3rd 
quartile vs. 1st quartile). bUnless specified, relative risk estimates are crude estimates. cMedian or mean and range of As concentration in drinking water included, when provided in the 
primary literature. dThe standard deviations presented in the study may be SEs. eRelative risk and 95% confidence interval as estimated by Navas-Acien et al. (2006). fCalculated by enter-
ing data presented in publication into OpenEpi software (Dean et al. 2011). gNumber of cases were not reported in original study, but were reported by Navas-Acien et al. (2006).
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on two alternative analyses did not (Steinmaus 
et al. 2009a, 2009b). Differences in methodo-
logical approaches used to characterize arsenic 
exposure in these studies are discussed in more 
detail below under “Urinary arsenic.”
Determining exposure and internal dose in 
studies of arsenic. Arsenic concentrations in 
drinking water. Measurement of total arsenic 
in drinking- water supplies is often used to 
assess arsenic exposure, but this approach is 
not appropriate for research questions per-
taining to individual exposures, including 
research concerning the effects of individual 
variation in arsenic metabolism on internal 
dose. Individual-level information on the 
magnitude, duration, and timing of exposure 
is critical, especially for estimating cumulative 
exposure. One alternative has been to combine 
historical measurements of arsenic concentra-
tions in drinking water with self-reported resi-
dential and water-use histories. This approach 
usually requires an assumption that arsenic 
concentrations in drinking water are stable 
over time and that study subjects do not con-
sume water from other sources. Support for 
these assumptions has been found in several 
study populations (Navas-Acien et al. 2009b; 
Ryan et al. 2000). 
Arsenic levels in blood, nails, and hair. 
The literature review revealed a number of 
arsenic exposure biomarkers in need of further 
characterization and validation. Whole blood 
and plasma are emerging exposure matrices 
that reflect a shorter half-life (i.e., about 1 hr) 
compared to arsenic levels in urine (4 days) 
(NRC 1999). Hair and nail arsenic levels 
are non invasive measures that reflect mean 
arsenic levels for exposures that occurred sev-
eral months (for hair) to over a year (for nails) 
before sampling (Orloff et al. 2009). Moreover, 
arsenic levels in nails generally reflect exposure 
to inorganic arsenic and seem to be less affected 
by seafood arsenicals (see below). While some-
times useful, hair is not a recommended expo-
sure matrix for arsenic (NRC 1999). One 
limitation of measuring arsenic in hair and nails 
is that arsenic speciation is difficult to conduct. 
Also, the time period of exposure captured by 
hair and nail measurements depends on the 
specific segments collected and analyzed. Other 
target tissues (e.g., urothelial cells) and buccal 
and saliva samples have also been suggested 
(Bartolotta et al. 2011; Hernández-Zavala et al. 
2008; Lew et al. 2010). Although these emerg-
ing biomarkers deserve additional attention, 
a more expanded knowledge of toxico kinetic 
data and information on correlations with 
existing biomarkers and intake doses is needed 
before they are adopted for use in research.
Urinary arsenic. One of the most com-
monly used measures of arsenic exposure is 
urine. However, measurements of total urinary 
arsenic will not distinguish between inorganic 
and organic forms of arsenic unless a speciated 
analysis is conducted. Distinguishing between 
the inorganic and organic forms of arsenic is 
important because the inorganic forms are 
generally accepted as being of greater toxico-
logical concern than the organic forms [Agency 
for Toxic Substances and Disease Registry 
(ATSDR) 2007; Vahter and Concha 2001]. 
The metabolism of inorganic arsenic is com-
plex and results in a number of metabolites, 
including some that are chemically unstable. 
Inorganic arsenic occurs in two oxidation 
states: arsenite (AsIII) and arsenate (AsV), 
where the Roman numeral refers to the oxi-
dation state. In the process of forming more 
water-soluble molecules, inorganic arsenic goes 
through alternating reduction and methyla-
tion reactions and fluctuates between oxidation 
states of III (regarded as more toxic) and V 
(less toxic) (ATSDR 2007; Vahter and Concha 
2001). The general characterization of oxida-
tion state III as less toxic than V is primarily 
based on acute toxicity studies, and this issue 
has not been adequately assessed in long-term 
toxicological studies. 
In any case, total urinary arsenic reflects 
the number of arsenic ions generated from all 
arsenic species in the urine, including inor-
ganic arsenic (AsIII, AsV), the tri- and penta-
valent methylated metabolites of inorganic 
arsenic [monomethylarsonite (MMAIII), dim-
ethylarsinite (DMAIII), monomethyl arsonate 
(MMAV), dimethyl arsinate (DMAV)] and 
the less toxic organic arsenic compounds com-
monly associated with dietary exposures, par-
ticularly in seafood (mainly arsenobetaine, 
arseno sugars, and arsenolipids) (Caldwell et al. 
2009; Navas-Acien et al. 2009b) [Figure 1; 
for detailed information on common forms of 
arsenic, see Supplemental Material, Table S2 
(http://dx.doi.org/10.1289/ehp.1104579)]. 
Because it is currently assumed that both the 
inorganic forms of arsenic and their methy-
lated metabolites may be associated with 
diabetes and other health risks, speciation 
analysis, including specification of the arsenic 
oxidation state, is recommended. Studies that 
do include a speciated analysis often do not 
include an oxidative state analysis to distin-
guish between tri- and pentavalent metabo-
lites of inorganic arsenic. In particular, there 
is a need to improve the ability to measure 
methylated trivalent species because they are 
regarded as more toxic (ATSDR 2007; Vahter 
and Concha 2001) and concentrations may be 
underestimated unless the appropriate specia-
tion analysis is conducted. Although techni-
cally challenging and not typically done, it is 
possible to conduct analyses of these metabo-
lites at the point of collection. 
Accounting for arsenic of seafood origin. 
Most human biomonitoring studies report 
levels of total arsenic, which includes inor-
ganic and organic arsenic compounds and their 
metabolites. Depending on location and diet 
of the population being studied, fish and other 
seafood can be a significant source of expo-
sure to specific organic forms of arsenic such as 
arsenobetaine, arseno sugars, and arseno lipids 
(Figure 1). Although they have not been eval-
uated as risk factors for  diabetes-related end 
points, these complex organic arsenic com-
pounds are generally accepted as less toxic than 
either inorganic arsenic or their methylated 
metabolites (ATSDR 2007; Vahter and Concha 
2001). Inorganic arsenic as well as methylated 
forms in oxidation state III are highly reac-
tive, with a high affinity for sulfhydryl groups 
(Vahter and Concha 2001). Therefore, failure 
to distinguish organoarsenicals from inorganic 
arsenic and metabolites of inorganic arsenic 
in urine may result in misclassification of 
exposure to the most toxicologically relevant 
forms of arsenic, which in turn may lead to 
mischaracterization of the association between 
urinary arsenic and diabetes. This is less of a 
concern when study participants are exposed to 
higher levels of arsenic from drinking water or 
proximity to an industrial or mining site with 
arsenic contamination because it is reason-
able to assume that urinary arsenic primarily 
reflects exposure to inorganic arsenic in these 
popula tions. However, in studies of the general 
Figure 1. Arsenic exposure and metabolism in the human body: from source to urine (modified from Navas-
Acien et al. 2009a).
aArsenic species measured in NHANES (Caldwell et al. 2009). Two other organic forms of arsenic considered to be minor 
contributors to arsenic in seafood were also measured in NHANES but were detected only in a small number of urine 
samples: arsenocholine (1.8%) and trimethylarsine oxide (0.3%). The predominant urinary metabolite of arsenocholine in 
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population, such as NHANES, a larger por-
tion of urinary arsenic may represent organic 
arsenic, mostly due to seafood consumption 
(Longnecker 2009; Navas-Acien et al. 2009a; 
Steinmaus et al. 2009a).
How to best adjust for organic arsenicals 
of seafood origin is a controversial topic 
[for a detailed discussion, see Supplemental 
Material, pp. 5–7 (http://dx.doi.org/10.1289/
ehp.1104579)]. Inorganic forms, arsenite and 
arsenate, are metabolized to their methylated 
forms, MMA and DMA, and eliminated in the 
urine. Although DMA is the major metabolite 
of inorganic arsenic, it is also a metabolite of 
the organic arsenicals, arseno sugars and arseno-
lipids and therefore reflects both exposures to 
inorganic and organic forms of arsenic of sea-
food origin (Figure 1). Three published strate-
gies have been used to address this issue using 
NHANES data: a) statistically adjusting mod-
els used to estimate the association between 
total urinary arsenic and diabetes for markers 
of seafood intake, such as levels of urinary arse-
nobetaine and blood mercury (Navas-Acien 
et al. 2008), b) restricting the analysis to par-
ticipants with very low or non detectable levels 
of arsenobetaine (Navas-Acien et al. 2009a), 
and c) subtracting any organic arsenicals (i.e., 
arseno betaine and arseno choline) above detec-
tion limits from the total urinary arsenic mea-
surement (Steinmaus et al. 2009a). These 
strategies led to different conclusions regard-
ing the association between inorganic arsenic 
and diabetes in NHANES, with the first two 
approaches resulting in statistically signifi-
cant associations (Navas-Acien et al. 2009a, 
2011), whereas the third suggested no asso-
ciation (Steinmaus et al. 2009a). Subtracting 
arsenobetaine from total urinary arsenic does 
not account for exposure misclassi fication due 
to the presence of other seafood arsenicals and 
their metabolites, which are included in total 
urinary arsenic measurements but cannot be 
specifically accounted for because they were 
not measured separately in the NHANES sam-
ples. Statistical adjustment for arsenobetaine 
and restriction to participants with low levels 
of arseno betaine control for all seafood arsenic 
species, not only for arseno betaine, and have 
shown consistent results (Navas-Acien et al. 
2009a, 2011). However, statistical adjustment 
may not completely eliminate bias because 
it mixes the effects of relevant and irrelevant 
exposures, and exclusion of seafood consum-
ers from analysis may lead to selection bias 
in populations where seafood consumption is 
common. The lack of consistency of findings 
based on the different analytical approaches 
described above warrants caution in interpret-
ing results from NHANES studies and high-
lights the importance of having good analytical 
methods to distinguish inorganic arsenic and its 
methyla ted metabolites from organic arsenicals 
of seafood origin.
Accounting for urine dilution. Typically, 
epidemiological studies that quantify exposure 
on the basis of spot urine measures for arsenic 
or other nonpersistent chemicals include 
adjustments for urine creatinine to account 
for variation in urine dilution. This may be 
accomplished by normalizing arsenic levels 
for creatinine as the exposure metric (i.e., 
micrograms of arsenic per gram urinary 
creatinine) or adjusting by using urinary 
arsenic as the measure of exposure (i.e., 
micrograms of arsenic per liter urine) but then 
including creatinine as a separate independent 
variable in the multiple regression analyses. 
Of the two approaches, the latter approach 
is recommended (Barr et al. 2005) because 
urinary creatinine concentrations are influenced 
by age, sex, health status, race/ethnicity, body 
mass index, fat-free mass, and time of day of 
collection and therefore can vary widely across 
individuals (Barr et al. 2005; Boeniger et al. 
1993; Mahalingaiah et al. 2008). However, 
this strategy may not be appropriate for 
metals or other chemicals that compromise 
kidney function.
The decision on how, or whether, to adjust 
for urinary creatinine concentration is more 
complicated when the health effect under inves-
tigation can impact creatinine levels, as is the 
case with diabetes (Greenland 2003). Persons 
with diabetes tend to have lower urinary 
concen tra tions of creatinine, in part because 
muscle mass is reduced as a consequence of 
diabetes, which results in reduced creatinine 
excretion (Park et al. 2009). Diabetes also 
leads to increased glomeru lar filtration and 
increased water intake, which can cause urine 
to be more dilute, resulting in lower urinary 
creatinine concen trations (Jerums et al. 2010). 
Both physiological processes may lead to biased 
assessments on the association between urinary 
arsenic and diabetes, although it is not possible 
to predict the direction of the overall bias with 
confidence (i.e., systematic bias toward or away 
from identifying a positive association). The 
reasons for this are discussed in more detail in 
the literature review document prepared for the 
2011 workshop (NTP 2011b). The situa tion 
is further complicated because arsenic expo-
sure has also been associated with increased 
urine creatinine in persons living in an arsenic-
endemic area of Bangladesh (Nermell et al. 
2008) or participating in the HEALS study 
described above (Ahsan H, personal commu-
nication). Thus, if diabetes and arsenic affect 
creatinine production, as well as urine dilution, 
then adjustment for creatinine may introduce 
bias rather than controlling measurement error 
induced by urine dilution (Greenland 2003). 
Relative risk estimates for associations between 
arsenic and diabetes based on creatinine- 
adjusted urine are quantitatively higher than 
estimates based on urinary arsenic levels that are 
not adjusted for creatinine (Chen et al. 2010; 
Steinmaus et al. 2009b). However, given the 
issues discussed above, it may not be possible to 
fully understand the potential bias with respect 
to clarifying the association between arsenic 
and diabetes. While specific gravity has been 
suggested as an alternative method to normalize 
urinary arsenic for differences in urine dilution 
because it appears to be less affected than crea-
tinine by age, sex, and body size (Mahalingaiah 
et al. 2008; Nermell et al. 2008), its use is not 
recommended in studies of diabetes because it 
is well established that specific gravity is not an 
accurate method if albumin or glucose is pres-
ent in the urine (Chadha et al. 2001; Voinescu 
et al. 2002). One approach to address concerns 
about creatinine adjustment is to report both 
raw and adjusted values. Prospective evidence, 
that is, measuring arsenic and creatinine at 
baseline and then during diabetes develop-
ment over the follow-up, remains the best 
strategy to eliminate potential bias related to 
the impact of diabetes in urine creatinine con-
centrations (i.e., before any potential renal or 
metabolic effect of the disease occurs in urine 
creatinine concentrations). 
Emerging issues related to arsenic expo-
sure. At present, there is very little exposure 
or toxicity information for other types of 
arsenicals. Roxarsone, an arsenic-based drug 
fed to chicken, turkeys, and pigs for growth 
promotion, feed efficiency, and improved 
pigmentation, may be a source of dietary 
exposure to inorganic arsenic (Food and 
Drug Administration 2011; Silbergeld and 
Nachman 2008). Thioarsenical metabolites in 
urine are emerging forms of concern but are 
difficult to measure and their interpretation is 
at present unclear (Naranmandura et al. 2010; 
Pinyayev et al. 2011). The significance of the 
gut microbiome in understanding arsenic tox-
icity is another new issue in the field. Available 
data suggest the impact of microbiome 
metabo lism of arsenic prior to absorption into 
the human body may be important in terms of 
interpreting observed differences in patterns of 
arsenic metabolites in addition to differences 
in metabolic pathways within human organs 
(Proctor 2011; Sun et al. 2012; Van de Wiele 
et al. 2010). 
Experimental Animal Studies
More than 20 animal studies published 
since 1979 were identified for this review, 
and they were primarily conducted with rats 
or mice (Figure 2). The existing studies are 
highly diverse, with considerable variation in 
the duration of treatment (1 day to 2 years), 
routes of administration, and in doses used 
in the studies. The most common routes of 
administration were oral, predominantly 
through drinking water or diet, or intraperi-
toneal injections. Other, less common forms 
of administration were gavage, oral capsules, 
or subcutaneous injection. Most of the studies 
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treated animals with AsIII or arsenic trioxide, 
but other arsenicals have also been studied 
(Aguilar et al. 1997; Arnold et al. 2003; Hill 
et al. 2009; Paul et al. 2008). The studies also 
vary in experimental design and model systems 
used to assess end points relevant to diabetes as 
a health effect, ranging from urinary glucose in 
fasted animals (Pal and Chatterjee 2005), to 
blood glucose in nonfasted animals (Mitchell 
et al. 2000), to glucose tolerance test (Cobo 
and Castineira 1997; Ghafghazi et al. 1980; 
Hill et al. 2009; Paul et al. 2007b, 2008, 2011; 
Wang et al. 2009). Glucose was a commonly 
reported end point but findings were incon-
sistent across studies, which may stem from 
differences in the biological compartment 
assessed (urine, serum, plasma, whole blood) 
and fasting status of the animal (fasted, non-
fasted, fasting status not reported) in addition 
to the differences in experimental design noted 
above related to arsenical tested, species, route 
of administration, and dose levels (Aguilar et al. 
1997; Arnold et al. 2003; Biswas et al. 2000; 
Boquist et al. 1988; Ghafghazi et al. 1980; Hill 
et al. 2009; Izquierdo-Vega et al. 2006; Judd 
1979; Mitchell et al. 2000; Pal and Chatterjee 
2004a, 2004b, 2005; Paul et al. 2007b, 2008, 
2011; Wang et al. 2009). Although the litera-
ture as a whole was judged inconclusive, find-
ings from recent studies that were designed to 
focus more specifically on diabetes-relevant end 
points appear, at least qualitatively, to support 
a link between arsenic exposure and diabetes. 
Supportive findings include impaired glucose 
tolerance in studies with mice (Boquist et al. 
1988; Hill et al. 2009; Paul et al. 2007b, 2011; 
Yen et al. 2007) or rats (Cobo and Castineira 
1997; Ghafghazi et al. 1980; Izquierdo-Vega 
et al. 2006; Singh and Rana 2009; Wang et al. 



















































Paul et al. 2007b AsIII Mouse, C57BL/6 (5 ♂) Drinking water 8 week (adult) [3.65, 5.13]a Glucose, blood (fasted)
Paul et al. 2011 AsIII Mouse, C57BL/6 (9–10 ♂) Drinking water 8 week (adult) [1.3*, 2.6*] + HFD Glucose, blood (fasted)
Paul et al. 2011 AsIII Mouse, C57BL/6 (9–10 ♂) Drinking water 8 week (adult) [2, 3] + LFD Glucose, blood (fasted)
Paul et al. 2008 AsIII Mouse, C57BL/6 (5 ♂) Drinking water 8 week (adult) [3.6, 4.7] Glucose, blood (fasted)
Boquist et al. 1988 AsIII Mouse, C57BL (5–10 ♂♀) Ip injection 1× (adult) 10* Glucose, blood (fasting NR)
Mitchell et al. 2000 AsIII Mouse, B6C3F1 (3 ♂) Ip injection 1× (adult) 0.1, 1 Glucose, blood (nonfasted)
Paul et al. 2007b AsIII Mouse, C57BL/6 (5 ♂) Drinking water 8 week (adult) [3.65, 5.13*] Glucose, GTT (ip), 2 hr
Paul et al. 2008 AsIII Mouse, C57BL/6 (5 ♂) Drinking water 8 week (adult) [3.6, 4.7*] Glucose, GTT (ip), 2 hr
Paul et al. 2011 AsIII Mouse, C57BL/6 (9–10 ♂) Drinking water 8 week (adult) [1.3, 2.6] + HFD Glucose, GTT (oral), 2 hr
Paul et al. 2011 AsIII Mouse, C57BL/6 (9–10 ♂) Drinking water 8 week (adult) [2, 3] + LFD Glucose, GTT (oral), 2 hr
Hill et al. 2009 AsV Mouse, LM/Bc/Fnn (6 ♀) Ip injection GD 7.5, 8.5 (adult) 9.6* Glucose, GTT (ip), 2 hr
Hill et al. 2009 AsV Mouse, LM/Bc/Fnn (6 ♀) Ip injection GD 7.5, 8.5 (adult) 9.6* Glucose, plasma (fasted)
Hill et al. 2009 AsV Mouse, LM/Bc/Fnn (10 ♀) Ip injection GD 7.5, 8.5 (adult) 9.6* Glucose, plasma (nonfasted)
Paul et al. 2008 MAsIII oxide Mouse, C57BL/6 (5 ♂) Drinking water 8 week (adult) [0.4, 0.9] Glucose, blood (fasted)
Paul et al. 2008 MAsIII oxide Mouse, C57BL/6 (5 ♂) Drinking water 8 week (adult) [0.4, 0.9] Glucose, GTT (ip), 2 hr
Judd 1979 MSMA Mouse, P. leucopus (9–10 [♂♀]) Drinking water 30 day (adult) [124.5*] Glucose, blood (fasting NR)
Paul et al. 2011 AsIII Mouse, C57BL/6 (9–10 ♂) Drinking water 8 week (adult) [1.3, 2.6*] + HFD HOMA-IR
Paul et al. 2011 AsIII Mouse, C57BL/6 (9–10 ♂) Drinking water 8 week (adult) [2, 3] + LFD HOMA-IR
Paul et al. 2011 AsIII Mouse, C57BL/6 (9–10 ♂) Drinking water 8 week (adult) [1.3*, 2.6*] + HFD Insulin, serum (fasted)
Paul et al. 2011 AsIII Mouse, C57BL/6 (9–10 ♂) Drinking water 8 week (adult) [2, 3] + LFD Insulin, serum (fasted)
Yen et al. 2007 AsIII oxide Mouse, CD-1 (ICR) (14 ♂) Drinking water 12 week (adult) [2.8*] Insulin, plasma (fasting NR)
Hill et al. 2009 AsV Mouse, LM/Bc/Fnn (6 ♀) Ip injection GD 7.5, 8.5 (adult) 9.6* HOMA-IR
Hill et al. 2009 AsV Mouse, LM/Bc/Fnn (6 ♀) Ip injection GD 7.5, 8.5 (adult) 9.6* Insulin, plasma (fasted)
Yen et al. 2007 AsIII oxide Mouse, CD-1 (ICR) (14 ♂) Drinking water 12 week (adult) [2.8*] Pancreatitis
Arnold et al. 2003 MMA Mouse, B6C3F1 (52 ♂) Diet 2 year (adult) [1.2, 6.0, 24.9, 67.1] Islet cell adenomas/carcinoma
Arnold et al. 2003 MMA Mouse, B6C3F1 (52 ♀) Diet 2 year (adult) [1.4, 7.0, 31.2, 101.1] Islet cell adenomas/carcinoma
Pal  and Chatterjee 2004a AsIII Rat, Wistar (6 ♂) Ip injection 21 day (adult) 5.55* Glucose, blood (fasted)
Pal  and Chatterjee 2004b AsIII Rat, Wistar (6 ♂) Ip injection 30 day (adult) 5.55* Glucose, blood (fasted)
Pal  and Chatterjee 2005 AsIII Rat, Wistar (6 ♂) Ip injection 30 day (adult) 5.55* Glucose, blood (fasted)
Wang et al. 2009 AsIII Rat, SD (5–8 ♂) Drinking water 140–210 day (adult) [0.6, 1.8, 3.6] Glucose, blood (fasting NR)
Ghafghazi et al. 1980 AsIII Rat, CD (4 ♂) Ip injection 7 day (adult) 5, 10* Glucose, blood (nonfasted)
Mitchell et al. 2000 AsIII Rat, SD (3 ♂) Ip injection 1× (adult) 0.1, 1 Glucose, blood (nonfasted)
Ghafghazi et al. 1980 AsIII Rat, CD (4 ♂) Ip injection 7 day (adult) 5, 10* Glucose, GTT (ip), 1 hr
Cobo and Castineira 1997 AsIII Rat, Wistar (7 ♂) Drinking water 8 week (adult) [0.57–2.17*] Glucose, GTT (oral), 2.5 hr
Wang et al. 2009 AsIII Rat, SD (5–8 ♂) Drinking water 182 day (adult) [0.6*, 1.8*, 3.6*] Glucose, GTT (oral), 2.5 hr
Izquierdo-Vega et al. 2006 AsIII Rat, Wistar (10 ♂) Oral (gavage) 90 day (adult) 3.4* Glucose, serum (fasted)
Pal  and Chatterjee 2005 AsIII Rat, Wistar (6 ♂) Ip injection 30 day (adult) 5.55* Glucose, urine (fasted)
Singh and Rana 2009 AsIII oxide Rat, Wistar (5 ♂) Ip injection 30 day (adult) 40* Glucose, serum (fasted)
Singh and Rana 2009 AsIII oxide Rat, Wistar (5 ♂) Ip injection 30 day (adult) 40 Insulin, serum (fasted)
Aguilar  et al. 1997 AsV oxide Rat, Wistar (5 ♂) Diet 10 week (adult) [2.5] Glucose, blood (nonfasted)
Arnold et al. 2003 MMA Rat, F344 (60 ♂) Diet 2 year (adult) [3, 25.7, 65.8–96.7*]b Glucose, blood (fasted)
Arnold et al. 2003 MMA Rat, F344 (60 ♀) Diet 2 year (adult) [3.9, 33.9, 67.9–116.8*]b Glucose, blood (fasted)
Izquierdo-Vega et al. 2006 AsIII Rat, Wistar (10 ♂) Oral (gavage) 90 day (adult) 3.4* Glucagon, serum (fasted)
Izquierdo-Vega et al. 2006 AsIII Rat, Wistar (10 ♂) Oral (gavage) 90 day (adult) 3.4* Glucose:insulin ratio (fasted)
Izquierdo-Vega et al. 2006 AsIII Rat, Wistar (10 ♂) Oral (gavage) 90 day (adult) 3.4* HOMA-IR
Izquierdo-Vega et al. 2006 AsIII Rat, Wistar (10 ♂) Oral (gavage) 90 day (adult) 3.4* Insulin, blood (fasting)
Izquierdo-Vega et al. 2006 AsIII Rat, Wistar (10 ♂) Oral (gavage) 90 day (adult) 3.4* Altered insulin/glucagon staining
Izquierdo-Vega et al. 2006 AsIII Rat, Wistar (10 ♂) Oral (gavage) 90 day (adult) 3.4* Oxidative stress
Mukherjee et al. 2006 AsIII Rat, Albino (5 ♂) Oral (not specified) 30 day (adult) 3* Oxidative stress
Mukherjee et al. 2006 AsIII Rat, Albino (5 ♂) Oral (not specified) 30 day (adult) 3* Pancreatic islet cells 
Arnold et al. 2003 MMA Rat, F344 (60 ♂) Diet 2 year (adult) [3, 25.7, 65.8–96.7]b Pancreatitis
Arnold et al. 2003 MMA Rat, F344 (60 ♀) Diet 2 year (adult) [3.9, 33.9, 67.9–116.8]b Pancreatitis
Mitchell et al. 2000 AsIII Guinea pig, Hartley (3 ♂) Ip injection 1× (adult) 0.1, 1* Glucose, blood (nonfasted)
Mitchell et al. 2000 AsIII Hamster, Golden-Syrian (3 ♂) Ip injection 1× (adult) 0.1, 1 Glucose, blood (nonfasted)
Biswas et al. 2000 AsIII Goat, Black Bengal (6 ♀) Oral (capsule) 12 week (adult) 25* Glucose, blood (nonfasted)
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Figure 2. Animal studies of arsenic and end points related to glucose homeostasis. Abbreviations: AsIII, arsenite; AsIII oxide, arsenic trioxide; AsV, arsenate; AsV 
oxide, arsenic pentoxide; GD, gestation day; GTT, glucose tolerance test; HFD, high-fat diet; HOMA-IR, homeostasis model assessment of insulin resistance; ip, 
intraperitoneal; LFD, low fat diet; MAsIII oxide, methylarsine oxide; MMA, monomethyl arsonate; NR, not reported.
aBracketed information indicates that the dose was converted to mg/kg from a different dose unit presented in the publication; use of brackets can also indicate that experimental 
details were not explicitly stated in the paper but could be reasonably inferred. bNotes on Arnold et al. (2003) rat findings: Effects on blood glucose in rats were only observed at 1 year 
of age, not at study completion at 2 years of age; the occurrence of pancreatitis was not statistically different in the high-dose group compared to controls, but there was a significant 
dose-related trend (p > 0.001) in both male and female rats. *p < 0.05; doses at which statistically significant effects were observed.
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2009). Measures of insulin regulation [i.e., 
HOMA-IR (homeostasis model assessment of 
insulin resistance), insulin sensitivity (Paul et al. 
2011)], as well as pancreatic effects [includ-
ing indicators of oxidative stress, degenerative 
changes in β-cells, and pancreatitis (Arnold 
et al. 2003; Boquist et al. 1988; Izquierdo-
Vega et al. 2006; Mukherjee et al. 2006; Yen 
et al. 2007)], have also been reported to be 
affected. Results from several animal studies 
suggest that cotreatment with methyl donors 
or antioxidants (e.g., folic acid, vitamin B12, 
methionine, N-acetyl cysteine) may attenu-
ate the effects of arsenic toxicity, including 
reductions in the degree of arsenic-induced 
pancreatic toxicity (Mukherjee et al. 2006) 
and arsenic-induced hyperglycemia (Pal and 
Chatterjee 2004a, 2004b, 2005). Although 
not directly assessing the potential diabeto genic 
effects of arsenic, Reichl et al. (1990) reported 
that cotreatment with glucose increased the 
survival rate in NMRI mice treated with a dose 
of AsIII oxide that resulted in 100% mortal-
ity when administered without the glucose 
(12.9 mg/kg by subcutaneous injection).
These studies suggest that animal models 
can be relevant to understanding the effects 
of arsenic on glycemic control depending on 
experimental design. Mice may be less suscep-
tible than humans to arsenic toxicity, partly 
due to a faster metabolism and clearance of 
arsenic, resulting in lower internal dose of 
inorganic arsenic species (Paul et al. 2007b, 
2008). Rats, unlike mice or humans, sequester 
arsenic (specifi cally DMA) in erythrocytes (Lu 
et al. 2004, 2007, 2008). It is unclear how this 
binding affects target organ dose of inorganic 
arsenic and rats are generally not recommended 
as a model for assessing arsenic metabolism or 
toxicity (NRC 1999).
Mechanisms
A number of in vitro studies implicate several 
pathways by which arsenic can influence pan-
creatic β-cell function and insulin sensitivity, 
including oxidative stress, glucose uptake and 
transport, gluconeogenesis, adipocyte differen-
tiation, and Ca2+ signaling (reviewed by Díaz-
Villaseñor et al. 2007; Druwe and Vaillancourt 
2010; Tseng 2004; see also Figure 3). Several 
of these pathways are discussed in more detail 
below, but in general the studies fall into the 
following categories: a) studies that use high 
concentrations of arsenic (≥ 1 mM) to examine 
stress response in various cell types, although 
the concentrations used limit interpretation 
because they are not considered physiologically 
relevant, resulting in cytotoxicity; b) studies 
that test lower concentrations (< 100 µM) of 
arsenic and report inhibition of insulin signal-
ing and insulin-dependent glucose uptake by 
adipocytes or myotubes (Paul et al. 2007b; 
Walton et al. 2004; Yen et al. 2010); and 
c) studies in insulinoma cell lines or isolated 
pancreatic islets that suggest that the mecha-
nisms by which arsenic affects β-cells to inhibit 
insulin expression and/or secretion are con-
centration dependent (Díaz-Villaseñor et al. 
2006, 2008; Fu et al. 2010; Pi et al. 2007). At 
relatively low concentrations (in the submicro-
molar range) certain adaptive cellular responses 
to arsenic-induced oxidative stress [i.e., induc-
tion of antioxidant enzymes and reduced 
reactive oxygen species (ROS)] may result in 
an impairment of glucose-stimulated insulin 
secretion (Fu et al. 2010; Pi et al. 2007). High 
concentrations result in irreversi ble damage 
(including oxidative damage) to β-cells fol-
lowed by apoptosis or necrosis (Macfarlane 
et al. 1997, 1999; Ortsater et al. 2002).
Influence of inorganic arsenic on glucose-
stimulated insulin secretion in pancreatic 
β-cells. Chronic oxidative stress leading to 
oxidative damage has long been implicated in 
Figure 3. In vitro studies related to arsenic and diabetes. Abbreviations: Δ, cytotoxicity reported at specified concentration level; aP2, fatty acid-binding protein; 
As2O3, arsenic trioxide; AsIII, arsenite; AsV, arsenate; Ca, calcium; C/EBPα, CCAAT/enhancer binding protein (C/EBP alpha); DMAIII oxide, dimethylarsine oxide; 
DMAV, dimethylarsinate; HIF1a, hypoxia inducible factor, alpha; HO1, heme oxygenase 1; IUF1, insulin upstream factor 1 (also known as PDX1); KLF5, Kruppel-
like factor 5; MAPKAP-K2, mitogen-activated protein kinase- activated protein kinase 2; MAsIII oxide, methylarsine oxide; MAsV, monosodium methylarsonate; 
Nrf2, transcription factor NF-E2–related factor 2; PDX1, pancreatic and duodenal homeobox 1 (also known as IUF1); PhAsO, oxophenylarsine; PPARγ, peroxisome 
proliferator-activated receptor γ; ROS, reactive oxygen species. 




Trouba et al. 2000 AsIII C3H 10T1/2 pre-adipocytes, mouse 0.1, 0.3, 1, 3*, 6*, 10* Adipocyte differentiation 
Wauson et al. 2002 AsIII C3H 10T1/2 pre-adipocytes, mouse 6* aP2, PPARγ, C/EBPα mRNA levels
Salazard et al. 2004 As2O3 3T3-F442A pre-adipocytes, mouse 0.005, 0.05, 0.25*, 0.5*, 1*, 5*, 15*, 25* PPARγ, C/EBPα expression 
Widnell et al. 1990 AsIII BHK cells, hamster 200*∆ Glucose transporter (altered distribution)
Walton et al. 2004 AsIII 3T3-L1 adipocytes, mouse 5, 10*, 20*, 50*∆, 100*∆ Glucose uptake
Fu et al. 2010 AsIII INS-1 (832/13) β cells, rat 0.05, 0.1, 0.25*, 0.5* Glucose-stimulated insulin secretion
Díaz-Villaseñor  et al. 2006 AsIII Isolated β cells, rat 1, 5* Glucose-stimulated insulin secretion
Díaz-Villaseñor et al. 2008 AsIII RINm5F β cells, rat 0.5, 1*, 2* Glucose-stimulated insulin secretion
Díaz-Villaseñor et al. 2008 AsIII RINm5F β cells, rat 0.5, 1, 2 Insulin synthesis
Paul et al. 2007a AsIII 3T3-L1 adipocytes, mouse 0.5, 5*, 10*, 25*, 50*, 100*, 500*, 5000* Insulin-stimulated glucose uptake 
Walton et al. 2004 AsV 3T3-L1 adipocytes, mouse 100*, 1000* Glucose uptake
Quintanilla et al. 2000 AsV Liver clone 9 cells, rat 200*∆ Glucose uptake
Orsater  et al. 2002 AsV ob/ob, isolated islets, mouse 5000*∆ Glucose-stimulated insulin secretion
Lu et al. 2011 As2O3 RINm5F β cells, rat 2*, 5* Insulin secretion
Walton et al. 2004 DMAIII oxide 3T3-L1 adipocytes, mouse 1, 2*, 5*∆, 10*∆ Glucose uptake
Walton et al. 2004 DMAV 3T3-L1 adipocytes, mouse 100, 1000 Glucose uptake
Walton et al. 2004 MAs V  3T3-L1 adipocytes, mouse 100*, 1000* Glucose uptake
Walton et al. 2004 MAsIII oxide 3T3-L1 adipocytes, mouse 0.25, 0.5, 1, 2*∆, 5*∆ Glucose uptake
Paul et al. 2007a MAsIII oxide 3T3-L1 adipocytes, mouse 0.5*, 1*, 2*, 5*, 10*,  20* Insulin-stimulated glucose uptake 
Widnell et al. 1990 PhAsO BHK cells, hamster 35*∆ Glucose transporter (altered distribution)
Scott et al. 2009 PhAsO L929 fibroblasts, mouse 0.5, 1, 2*, 5*, 10*, 20*, 30*, 40* Glucose uptake
Liebl  et al. 1995a, 1995c PhAsO MDCK cells, dog 1, 2*, 5*, 10* Glucose uptake
Liebl  et al. 1995b PhAsO MDCK cells, dog 1, 2, 5, 10*, 20*, 50*, 100* Glucose uptake
Fu et al. 2010 AsIII INS-1 (832/13) β cells, rat 0.05, 0.1, 0.25*, 0.5* Cellular oxidative stress
Díaz-Villaseñor et al. 2008 AsIII RINm5F β cells, rat 0.5*, 1*, 2* Intracellular [Ca2+]
Macfarlane et al. 1997 AsIII Isolated islet cells, human 1000*∆ IUF1 binding to DNA
Macfarlane et al. 1997 AsIII MIN6 β cells, mouse 1000*∆ MAPKAP-K2 activity
Fu et al. 2010 AsIII INS-1 (832/13) β cells, rat 0.05*, 0.1*, 0.25*, 0.5* Nrf2 protein in nucleus
Macfarlane et al. 1999 AsIII Isolated islet cells, human 1000*∆ PDX1 activation and translocation to nucleus
Salazard et al. 2004 As2O3 3T3-F442A pre-adipocytes, mouse 0.005, 0.05, 0.25*, 0.5*, 1*, 5*, 15*, 25* Cell cycle c-Jun, KLF5 expression 
Salazard et al. 2004 As2O3 3T3-F442A pre-adipocytes, mouse 0.005, 0.05, 0.25*, 0.5*, 1*, 5*, 15*, 25* HO1, HIF1a expression 
Yen et al. 2007 As2O3 HIT-T15 β-cells, hamster 5*, 7.5*, 10, 20* ROS
Lu et al. 2011 As2O3 RINm5F β cells, rat 2*, 5* ROS
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β-cell dysfunction in diabetes. Oxidative stress 
is also implicated in many aspects of arsenic 
toxicity, and a recent in vitro study suggests 
that transcription factor NF-E2–related fac-
tor 2 (Nrf2)-mediated antioxidant response 
may influence arsenite-induced impairment 
of glucose-stimulated insulin secretion in 
β-cells at low concentrations of arsenite (Fu 
et al. 2010). The transcription factor Nrf2 is 
a key cellular component that defends cells 
against toxicities of oxidants and electro-
philes by regulating both constitutive and 
inducible expression of many antioxidant/ 
detoxification enzymes (Fu et al. 2010; He 
and Ma 2010). Although antioxidants are 
generally considered protective for cells, this 
same Nrf2-driven induction of endogenous 
antioxidant enzymes meant to maintain intra-
cellular redox homeostasis and limit oxidative 
damage may also have a negative impact on 
insulin secretion by diminishing the avail-
ability of ROS, such as hydrogen peroxide 
(H2O2). Reactive oxygen species’ signals pro-
duced during glucose metabolism are becom-
ing recognized as intra cellular regulators of 
glucose-stimulated insulin secretion acting to 
increase insulin secretion (Leloup et al. 2009; 
Pi et al. 2007, 2010).
Thus, the Nrf2-mediated antioxidant 
response appears to play paradoxical roles in 
β-cell function by a) blunting glucose- triggered 
ROS signaling and thus resulting in reduced 
glucose-stimulated insulin secretion, and 
b) protecting β-cells from oxidative damage 
and subsequent apoptosis/necrosis (Fu et al. 
2010). Chronic exposure to inorganic arsenic 
and the production of its methylated tri valent 
metabolites have been linked to oxidative 
stress; however, at the levels generally expected 
in low-to-moderate human exposures, they are 
not likely to reach cytotoxic concentrations suf-
ficient to cause irreversible damage, although at 
these levels they may activate Nrf2. Therefore, 
premise a above is potentially more relevant to 
β-cell dysfunction in the context of low-level 
environ mental arsenic exposure, whereas prem-
ise b might be associated with β-cell damage 
and failure induced by high doses of arsenic. 
Influence of trivalent arsenicals on glucose 
uptake in adipocytes and skeletal muscle cells. 
Type 2 diabetes is characterized by disruptions 
in whole-body glucose homeostasis due to 
insulin resistance and impaired glucose utiliza-
tion by peripheral tissues, including skeletal 
muscle and adipose tissue. Results of tissue 
culture studies suggest that arsenite and/or its 
methylated trivalent metabolites cause insulin 
resistance in adipocytes by inhibiting insulin 
signaling and insulin-activated glucose uptake. 
Arsenite can also interfere with the formation 
of insulin-sensitive adipocytes and myotubes 
by inhibiting adipogenic and myogenic dif-
ferentiation (Salazard et al. 2004; Trouba et al. 
2000; Walton et al. 2004; Yen et al. 2010).
Arsenite and its metabolites interact with a 
number of elements involved in insulin signal-
ing, including insulin receptor substrate (IRS), 
phosphatidylinositol-3 kinase (PI3K), AKT, 
phosphoinositide-dependent kinase (PDK), 
and protein kinase C (PKC). AKT belongs to 
a class of enzymes important in regulating glu-
cose metabolism, cell proliferation, apoptosis, 
transcription, and cell migration (Paul et al. 
2007a; Walton et al. 2004). Insulin stimulates 
glucose uptake by binding to the insulin recep-
tor and activating the IRS-1, IRS-2, PI3K, 
PDK, AKT, and/or PKC-ζ/PKC-λ signaling 
pathway(s) (Choi and Kim 2010; Standaert 
et al. 1999). Activation of PKC-ζ and PKC-λ 
stimulates Ras-related protein (RAB4A) activ-
ity, the association of RAB4A with kinesin-
like protein KIF3B, and the interaction 
of KIF3B with microtubules. This process 
is essential for recruitment of glucose trans-
porter type 4 (GLUT4) to the cytoplasmatic 
membrane and for insulin-dependent glucose 
uptake (Imamura et al. 2003; Lee et al. 2010). 
Subcytotoxic concentrations in the micro-
molar range of arsenite and its methylated 
trivalent metabolites, MMAIII and DMAIII, 
inhibit insulin- stimulated glucose uptake in 
cultured adipocytes by interfering with the 
phosphoryla tion of AKT-dependent mobiliza-
tion of GLUT4. Arsenite and MMAIII inhibit 
PDK-catalyzed phosphorylation of AKT in 
the insulin signaling cascade; DMAIII inhib-
its GLUT4 trans location by interfering with 
the signaling step(s) downstream from AKT 
(Paul et al. 2007a; Walton et al. 2004). The 
adaptive anti oxidant response associated with 
prolonged exposure to relatively low concentra-
tions of arsenite in the 1–2 µM range have also 
been associated with suppression of insulin-
 stimulated AKT phosphorylation and glucose 
uptake in 3T3-L1 adipocytes causing an insu-
lin resistant phenotype (Xue et al. 2011).
Insulin resistance is a hallmark of diabetes 
and the role of adipocytes in mediating insu-
lin resistance is an active area of research. A 
number of studies have assessed the impact of 
arsenic on adipocytes. Arsenite inhibits and 
reverses differentiation of adipocytes by dis-
rupting the expression of the genes involved in 
adipogenesis (Wauson et al. 2002). Expression 
of both peroxisome proliferator-activated 
receptor-γ (PPARγ) and CCAAT/enhancer-
binding protein α (C/EBPα) is required for 
phenotypic differentiation of adipocytes, and 
arsenite inhibits expression of both of these 
transcription factors. Arsenite disrupts the 
interaction between PPARγ and its coactiva-
tor retinoid X receptor alpha (RXRα). Arsenic 
trioxide also inhibits AKT binding to PPARγ 
(Wang et al. 2005). Inhibition of these tran-
scription factors reduces expression of PPARγ 
and C/EBPα target genes: adipocyte fatty acid 
binding protein (A-FABP), which is involved 
in preadipocyte differentiation, and p21, 
a protein whose expression is tightly regu-
lated during adipogenesis (Wang et al. 2005; 
Wauson et al. 2002). Inhibition of p21 leads 
to activation of preadipocyte proliferation, 
thereby inhibiting adipocyte differentiation 
(Wang et al. 2005). 
Myogenesis is associated with the develop-
ment of the insulin-responsive glucose transport 
system and there are indications that arsenite 
may have similar effects on myogenic differ-
entiation; however, this has not been studied 
to the same extent as its effects on adipo cytes. 
Pathways mediating muscle differentia tion 
include insulin-dependent activation of AKT/
mTOR/p70 S6 kinase1/MEF2C/MYOD/
MYOG signaling (Conejo et al. 2002; Xu and 
Wu 2000). Low concentrations (e.g, 20 nM) 
of arsenite have been shown to delay the dif-
ferentiation of muscle cells from myoblasts to 
myotubes by repressing the transcription fac-
tor myogenin (Steffens et al. 2010). Arsenite 
also significantly decreases the phosphorylation 
of AKT and its downstream targets, mTOR 
and p70 S6 kinase1 proteins, during myogenic 
differentiation (Yen et al. 2010). Inhibition 
of AKT by arsenite was also demonstrated in 
muscle cells (Yen et al. 2010), and may lead 
to a reduction in glucose uptake in this tissue 
(Díaz-Villaseñor et al. 2007).
Conclusions and Research 
Needs
Overall, data from human studies included 
in this review support an association between 
inorganic arsenic and diabetes in popula-
tions with arsenic drinking- water levels of 
> 500 µg/L (Lai et al. 1994; Nabi et al. 2005; 
Rahman et al. 1998, 1999; Tsai et al. 1999; 
Tseng et al. 2000b; Wang et al. 2003), but the 
currently available evidence was considered 
insufficient to conclude that arsenic is asso-
ciated with diabetes in individuals with low-
to-moderate exposure (< 150 µg/L in drinking 
water). Stronger evidence of associations at 
lower levels of exposure based on some recent 
studies with better measures of outcome and 
exposure support the need for further research 
in populations with low-to-moderate exposure 
levels. Weaknesses noted in the epidemiological 
literature review included a lack of prospective 
studies, use of death certificates or self-reported 
diagnosis for ascertainment of diabetes, and 
ecological methods of exposure assessment. 
Because of these limitations, the evidence of 
effects at high arsenic exposure levels ranged 
from limited to sufficient, but did not reach 
the threshold for a sufficient classification.
Research needs identified as a result of this 
literature review are summarized in Table 3. 
Prospective studies in areas of lower expo-
sure (e.g., parts of North America other than 
arsenic-endemic regions) with individual mea-
surements of exposure prior to disease incidence 
are needed. However, the utilization of existing 
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cohorts (such as the Strong Health Study), 
nested case–control designs, and follow-up of 
cross-sectional populations such as NHANES 
is also recommended. Additional consideration 
of the results from the recent HEALS study in 
Bangladesh (Chen et al. 2010), which do not 
align with findings from other studies in areas 
of moderate-to-high exposure, would also be 
helpful to better understand factors that influ-
ence the generalizability of associations reported 
based on other study populations. Research 
on interactions between arsenic exposure and 
factors such as body mass index (BMI), diet, 
levels of physical activity, co-exposures includ-
ing metals that occur with arsenic, duration 
of exposure, and timing of exposure (i.e., the 
importance of early life or prenatal exposures) 
may help address this issue. In addition, future 
studies should include consideration of gene 
× environ ment interactions, including studies 
of polymorphisms in genes related to arsenic 
metabolism and diabetes susceptibility.
Given its well-established role as a risk factor 
for diabetes, the impact of obesity as a potential 
modifying factor needs to be better addressed, 
especially in countries such as the United 
States and Mexico where overweight and obe-
sity are epidemic (WHO 2012). Average BMI 
in Bangladesh and Taiwan, where the asso-
ciation between arsenic exposure and diabetes 
was stronger, is much lower than in the United 
States and Mexico. For example, approximately 
80% of study participants in the HEALS study 
in Bangladesh had a BMI of < 22 (Chen et al. 
2010) whereas 68% of study participants 
included in the analysis of NHANES 2008 had 
a BMI of ≥ 25 (Navas-Acien et al. 2008). In the 
Mexico studies, 34–50% of participants had a 
BMI of > 30 (Coronado-González et al. 2007; 
Del Razo et al. 2011). Information on BMI was 
not presented in most of the studies conducted 
in Taiwan except for Tseng et al. (2000b), 
where the average BMI was 24.5 kg/m2; 
although as a population, the prevalence of 
overweight/obesity is higher in Taiwan com-
pared to Bangladesh and lower compared to 
the United States (Huang 2008; WHO 2012). 
Many of the recent studies considered BMI as a 
potential confounding factor (Chen et al. 2010; 
Coronado-González et al. 2007; Del Razo et al. 
2011; Ettinger et al. 2009; Kim and Lee 2011; 
Lai et al. 1994; Navas-Acien et al. 2008, 2009a; 
Rahman et al. 1999; Steinmaus et al. 2009a, 
2009b; Tseng et al. 2000b), but the issue of 
obesity as an effect modifier or potential inter-
mediate on a causal pathway between arsenic 
and diabetes has not been well-explored in the 
existing literature.
The experimental animal literature as 
a whole was judged inconclusive, but find-
ings from recent studies that focus on 
diabetes- relevant end points appear consis-
tent with those human studies that support a 
link between arsenic exposure and diabetes. 
Moreover, the animal studies implicate several 
pathways by which arsenic may influence pan-
creatic β-cell function and insulin sensitivity 
and suggest novel biomarkers for understand-
ing pathways of response to arsenic in human 
populations. However, animal studies need to 
be designed to be relevant to human exposures 
in terms of internal dose. Use of specific inbred 
strains susceptible to diabetes and metabolic 
syndrome may also be informative. Application 
of systems toxicology approaches within the 
framework utilized by the NIEHS and oth-
ers in studying relevance of the “toxome” [a 
comprehensive list of all pathways of toxicity 
(Hartung and McBride 2011)] to the “diabe-
tome” [a conceptual platform placing a disease, 
diabetes, onto a network perspective and link-
ing diabetes phenotypic features to all known 
diabetes-related genes (modified from Goh and 
Choi 2012)] may be innovative and stimulate 
new information on key signaling pathways 
that connect arsenic to diabetes.
Overall, animal studies need to be designed 
to specifically evaluate the influence of arsenic 
on the development of diabetes, using modern 
methods and well characterized end points for 
diabetes. Blood glucose levels, both fasting and 
fed, as well as insulin levels were identified as 
appropriate end points for animal studies. The 
influence of adiposity on the development of 
arsenic-induced diabetes could be explored 
more fully in animal models by quantitating 
fat mass and distribution in both white and 
brown adipose tissues.
Improved methodologies are needed for 
more accurate environ mental exposure assess-
ments as well as for internal dosemetrics and 
biologically based measurements that inte-
grate all and differentiate among exposures, 
metabolites, and toxicities. Some of the newer 
proposed biomarkers (e.g., toe- and finger-
nails, saliva, buccal cells) need to be further 
characterized in terms of their relationships to 
 external exposures and validated. 
correction
There were errors in the manuscript originally 
published online. In the “Conclusion” of the 
Abstract and in the titles of Tables 1 and 2, 
the exposure levels for arsenic should have 
been given as “µg/L” instead of “µg/µL” or 
“ppm.” The errors have been corrected here.
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